Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer. by Aliu, B. et al.
486  |    Journal of Neurochemistry. 2020;154:486–501.wileyonlinelibrary.com/journal/jnc
 
Received: 21 November 2019  |  Revised: 11 March 2020  |  Accepted: 18 March 2020
DOI: 10.1111/jnc.15021  
O R I G I N A L  A R T I C L E
Selective inhibition of anti-MAG IgM autoantibody binding to 
myelin by an antigen-specific glycopolymer
Butrint Aliu1  |   Delphine Demeestere1  |   Emilie Seydoux2  |   José Boucraut3,4  |   
Emilien Delmont5  |   Alexandre Brodovitch3,5 |   Thomas Oberholzer2 |   
Shahram Attarian5  |   Marie Théaudin6  |   Pinelopi Tsouni6  |   Thierry Kuntzer6  |   
Tobias Derfuss7  |   Andreas J. Steck7 |   Beat Ernst1  |   Ruben Herrendorff1,2 |   
Pascal Hänggi1,2
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry
Butrint Aliu and Delphine Demeestere contributed equally to this work. 
Abbreviations: BSA, bovine serum albumin; BTU, Bühlmann titer units; CANOMAD, chronic ataxic neuropathy ophthalmoplegia M-protein agglutination disialosyl antibodies syndrome; 
CIDP, chronic inflammatory demyelinating polyneuropathy; DC, dendritic cells; EBV, Epstein–Barr virus; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; HNK-1, 
human natural killer-1; LPS, lipopolysaccharide; MAG, myelin-associated glycoprotein; MFI, mean fluorescence intensity; MGUS, monoclonal gammopathy of unknown significance; 
PBMC, peripheral blood mononuclear cells; PBS, phosphate-buffered saline; PPSGG, poly(phenyl disodium 3-O-sulfo-β-d-glucopyranuronate)-(1→3)-β-d-galactopyranoside; RPMI, 
Roswell Park Memorial Institute medium; SGPG/SGLPG, sulfoglucuronyl paragloboside/sulfoglucuronyl-lactosaminyl-paragloboside.
1Institute of Molecular Pharmacy, 
Department of Pharmaceutical Sciences, 
University of Basel, Basel, Switzerland
2Polyneuron Pharmaceuticals AG, Basel, 
Switzerland
3Immunology laboratory, AP-HM, Marseille, 
France
4INT, UMR CNRS 7289, Aix-Marseille 
University, Marseille, France
5Center for Neuromuscular Disorders and ALS 
La Timone Hospital, AP-HM, Marseille, France
6Nerve-Muscle Unit, Service of Neurology, 
Department of Clinical Neurosciences, 
Lausanne University Hospital (CHUV) and 
University of Lausanne, Lausanne, Switzerland
7Clinic of Neurology, Department of 
Medicine, University Hospital Basel, 
University of Basel, Basel, Switzerland
Correspondence
Pascal Hänggi, Polyneuron Pharmaceuticals 




Neuromuscular Research Association Basel; 
Gebert Rüf Stiftung, Grant/Award Number: 
GRS-044/15; Kommission für Technologie 
und Innovation, Grant/Award Number: 
17485.1 PFLS-LS
Read the Editorial Highlight for this article on page 
465. 
Abstract
Anti-myelin-associated glycoprotein (MAG) neuropathy is a disabling autoimmune 
peripheral neuropathy that is caused by circulating monoclonal IgM autoantibod-
ies directed against the human natural killer-1 (HNK-1) epitope. This carbohydrate 
epitope is highly expressed on adhesion molecules such as MAG, a glycoprotein pre-
sent in myelinated nerves. We previously showed the therapeutic potential of the 
glycopolymer poly(phenyl disodium 3-O-sulfo-β-d-glucopyranuronate)-(1→3)-β-d-
galactopyranoside (PPSGG) in selectively neutralizing anti-MAG IgM antibodies in 
an immunological mouse model and ex vivo with sera from anti-MAG neuropathy 
patients. PPSGG is composed of a biodegradable backbone that multivalently pre-
sents a mimetic of the HNK-1 epitope. In this study, we further explored the phar-
macodynamic properties of the glycopolymer and its ability to inhibit the binding of 
anti-MAG IgM to peripheral nerves. The polymer selectively bound anti-MAG IgM 
autoantibodies and prevented the binding of patients’ anti-MAG IgM antibodies to 
myelin of non-human primate sciatic nerves. Upon PPSGG treatment, neither activa-
tion nor inhibition of human and murine peripheral blood mononuclear cells nor al-
teration of systemic inflammatory markers was observed in mice or ex vivo in human 
peripheral blood mononuclear cells. Intravenous injections of PPSGG to mice immu-
nized against the HNK-1 epitope removed anti-MAG IgM antibodies within less than 
1 hr, indicating a fast and efficient mechanism of action as compared to a B-cell de-
pletion with anti-CD20. In conclusion, these observations corroborate the therapeu-
tic potential of PPSGG for an antigen-specific treatment of anti-MAG neuropathy.
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1  | INTRODUC TION
Anti-myelin-associated glycoprotein (MAG) neuropathy is a rare 
form of acquired demyelinating polyneuropathy associated with IgM 
monoclonal gammopathy of neurological significance commonly 
referred as monoclonal gammopathy of undetermined significance 
(Talamo, Mir, Mir, Pandey, Sivik, & Raheja, 2015). Typically, the dis-
ease onset occurs after the age of 50 years and is 2.7 times more 
frequent in men than in women (Vallat et al. 2016) with a prevalence 
of about 1 in 100,000 (Heesters, van der Poel, Poel, Das, & Carroll, 
2016; Mahdi-Rogers & Hughes, 2014; Mygland & Monstad, 2001; 
Talamo et al., 2015). This gammopathy of neurological significance 
leads to the production of monoclonal anti-MAG IgM antibodies 
that recognize the human natural killer-1 (HNK-1) epitope, which 
is highly expressed on adhesion molecules such as MAG in the pe-
ripheral nervous system (Quarles, 2007; Steck, Stalder, Stalder, & 
Renaud, 2006). MAG, a member of the sialic acid-binding Ig-like 
lectins (siglecs), is located in the periaxonal membranes of oligo-
dendroglial cells of the central nervous system and in Schwann cells 
of the peripheral nervous system (PNS), where it is localized in the 
paranodal loops and Schmidt-Lanterman incisures (Dalakas, 2010; 
Erb et al., 2006; Kelm et al., 1994). MAG is a mediator for the forma-
tion and maintenance of the myelin sheaths (Tang et al., 1997). Anti-
MAG IgM autoantibodies recognize the HNK-1 epitope, the sulfated 
trisaccharide 3-O-sulfo-β-d-GlcA-(1→3)-β-d-Gal-(1→4)-d-GlcNAc, 
which is expressed mainly on the glycoprotein MAG but also on 
PMP22 and glycolipids such as sulfoglucuronyl-paragloboside, and 
sulfoglucuronyl-lactosaminyl-paragloboside (Quarles, 2007). Nerve 
biopsies from affected patients show demyelination and widening of 
myelin lamellae (Ritz et al., 1999; Steck, Murray, Murray, Meier, Page, 
& Perruisseau, 1983). There is strong evidence that the deposition of 
anti-MAG IgM on myelin sheath and myelin lamellae is responsible 
for the demyelination, which clinically manifests itself as a peripheral 
neuropathy affecting primarily sensory nerves (Gabriel et al., 1998; 
Latov et al., 1981; Willison et al., 1988). Patients suffer from sen-
sory ataxia with impaired gait, paresthesia, distal muscle weak-
ness, and tremor (Braun, Frail, Frail, & Latov, 1982; Dalakas, 2010; 
Steck et al., 1983). Progression of the chronic neuropathy is linked 
to the presence of anti-MAG IgM antibodies and there is evidence 
that the reduction in anti-MAG IgM titers leads to clinical improve-
ments (Benedetti et al., 2007; Gabriel et al., 1996; Nobile-Orazio 
et al., 1988; Pestronk et al., 2003; Renaud et al., 2006; Steck 
et al., 2006). However, the causes and the exact mechanisms behind 
the expansion of anti-MAG IgM producing B-cell clones are not fully 
understood.
Most off-label treatments aim to reduce pathogenic autoan-
tibody titers by depleting autoantibody-producing B-cell clones, 
interfere with antibody-effector mechanisms, or physically remove 
autoantibodies from the circulation. Most frequently, the anti-CD20 
monoclonal antibody rituximab is used to treat anti-MAG neurop-
athy patients (Dalakas, 2010; Lunn & Nobile-Orazio, 2016; Steck 
et al., 2006). However, all of these treatment options lack selectivity, 
efficiency, or can induce severe adverse effects in some patients. 
For example, acute worsening of the condition related to an IgM 
flair and concurrent rise in anti-MAG IgM plasma titers has been 
described after rituximab treatment (Broglio & Lauria, 2005; Sala, 
Robert-Varvat, Paul, Camdessanché, & Antoine, 2014).
In a previous study, we described the glycopolymer poly(phe-
nyl disodium 3-O-sulfo-β-d-glucopyranuronate)-(1→3)-β-d-
galactopyranoside (PPSGG) designed to specifically target the 
pathogenic anti-MAG IgM autoantibodies as a potential drug can-
didate for the treatment of anti-MAG neuropathy (Herrendorff 
et al., 2017). The glycopolymer is composed of a biodegradable 
poly-l-lysine backbone (≈ 80 kDa) presenting multiple copies of a 
mimetic of the sulfated HNK-1 trisaccharide to facilitate a multiva-
lent interaction with anti-MAG IgM autoantibodies. We previously 
showed in a competitive ELISA that PPSGG prevented the binding 
of patients’ anti-MAG IgM autoantibodies to MAG at low nanomolar 
concentrations. Furthermore, we demonstrated a highly efficient re-
duction in anti-MAG IgM antibody titers in an immunological mouse 
model for anti-MAG neuropathy. In this study, the pharmacodynamic 
properties and potential immunomodulatory effects of PPSGG were 
further investigated. PPSGG was found to selectively and efficiently 
inhibit the binding of patients’ anti-MAG IgM to sciatic nerve myelin 
of non-human primates. Furthermore, the pharmacodynamic profile 
of the glycopolymer was characterized, including a dose titration 
study in mice to predict the estimated dose required in anti-MAG 
neuropathy patients. Finally, it was shown that PPSGG removes the 
anti-MAG IgM autoantibodies in a highly selective fashion without 
the activation of murine or human immune cells.
2  | METHODS
2.1 | Patients and control blood samples
All experiments using human samples were performed in accordance 
with the Declaration of Helsinki (1964, Association H. E. C. o. E. o. t. W. 
M. 1964). Patients and control subjects signed the written informed 
consent for their participation in this study. The study was not pre-
registered and the protocol was approved by the Ethical Committees 
EKNZ, and CER-VD (Commission cantonale d'éthique de la recherche 
sur l'être humain), Switzerland (Study Nr. 01551). Heparinized whole 
blood of patients with clinically confirmed anti-MAG neuropathy 
K E Y W O R D S
antigen-specific treatment, anti-MAG IgM autoantibodies, demyelinating peripheral 
neuropathy, monoclonal gammopathy of neurological significance, myelin-associated 
glycoprotein
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and healthy control subjects were obtained from the Department of 
Neurology of the University Hospital Basel (Basel, Switzerland), the 
Lausanne University Hospital (Lausanne, Switzerland), and Centre 
Hospitalier de la Timone, AP-HM (Assistance Public-Hôpitaux de 
Marseille), (Marseille, France). The blood samples of the anti-MAG 
patients were taken during regular visit at the center and the control 
samples were taken in the morning.
2.2 | Experimental animals
The wild type BALB/cJRj (Ref. C-BJ-56-M/F; Janvier Labs) mice 
(5–10 weeks old male and female (n = 61) used in this study were 
bred at the University Hospital Basel and kept under specific path-
ogen-free conditions in a controlled environment (12-hr light–dark 
cycle at 20°C) with food and water ad libitum. Unless stated, experi-
ments were performed in the morning without blinding of the ex-
perimenter. Mice were allocated arbitrarily into the different groups 
and the dosing was increased from low to high. No anesthetic or 
medication was required to reduce treatment related effects and 
no animal was excluded or died during the studies. Mice were sacri-
ficed by CO2 suffocation and decapitation after the last blood sam-
pling (Figure 1). The power calculation was based on the previous 
study (Herrendorff et al., 2017) where the null hypothesis was dis-
proved and showed a concentration-dependent relationship of the 
PPSGG and the anti-MAG IgM binding (>80% relative reduction in 
F I G U R E  1   Flow chart of the animal experiments. Overview of the timelines of the animal experiments (n = 61). Images 
adapted from SMART Servier Medical ART
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the anti-MAG IgM titers in the dose range of 2–10 mg/kg in mice). 
Therefore, we assume an alternative hypothesis (µA − µB ≠ 0) for 
the primary endpoint that states that the anti-MAG IgM antibod-
ies can be neutralized and removed by PPSGG in vivo compared to 
vehicle (phosphate-buffered saline, PBS) treatment (one-tailed) to 
have a power of >80% and a type I error of 5%, we would need six 
subjects per group to prove the effect is significant (2 independent 
means, one-sided, µA = 100, µB = 20, κ = nA/nB = 1, σ = 20). The study 
was not pre-registered and all animal experiments were performed 
in accordance with authorization No. 2778 of the Animal Research 
Authorities of the Canton of Basel-Stadt, Switzerland.
2.3 | Isolation and culture of human PBMC, B 
cells, and DC
Peripheral blood mononuclear cells (PBMC) were isolated from hep-
arinized blood samples by gradient centrifugation according to the 
protocol provided by GE-Healthcare (Ficoll-Paque PLUS). B cells 
(CD19+) and monocytes (CD14+, CD16-) were isolated from PBMC by 
negative selection using the EasyEights™ EasySep™ Magnet (18103), 
the EasySep™ Human B Cell Isolation Kit (17954), and the EasySep™ 
Human Monocyte Isolation Kit (19359) all provided by StemCell™ 
Technologies.
B cells were maintained for up to 2 days in Roswell Park 
Memorial Institute medium (RPMI) 1640 medium (R8758, Roswell 
Park Memorial Institute medium; Sigma-Aldrich), supplemented with 
10% fetal bovine serum (FBS, 10270–106), 1% antibiotic-antimy-
cotic solution (AA, 15240062), and 1% l-glutamine solution (l-Gln, 
11500626) all provided by Gibco, Thermo Fisher Scientific.
Monocytes were seeded and differentiated to dendritic cells 
(DC) in complete RPMI 1640 medium containing 10% FBS, 1% AA, 
1% l-Gln and supplemented with 800 IU/ml recombinant GM-CSF 
(Granulocyte macrophage colony-stimulating factor) and 500 IU/ml 
recombinant IL-4 (R&D Systems) for 6 days at 37°C and 5% CO2.
2.4 | Ex vivo Epstein–Barr transformation of B cells
To prolong the viability of primary human B cells (n = 4 anti-MAG 
neuropathy patients) ex vivo, the cells were transformed with 
Epstein-Barr virus (EBV) (Hollyoake, Stühler, Stühler, Farrell, Gordon, 
& Sinclair, 1995). Marmoset B95.8 Epstein–Barr virus-producing 
cells (RRID:CVCL_1953; Vircell) were maintained in complete RPMI 
1640 medium containing 10% FBS, 1% AA, and 1% l-Gln. The super-
natant containing the EBV was collected after 20 days by centrifug-
ing cells (1400g, 15 min) and filtering the supernatant with a 0.45 μm 
and a 0.2 μm Filtropur S filter (83.1826; Sarstedt). Freshly isolated 
human PBMC (1x106 cells) were resuspended in 3 ml EBV superna-
tant and incubated for 24 hr before adding 7 ml complete RPMI 1640 
medium supplemented with 20 ng/ml cyclosporin A (30024; Sigma-
Aldrich). The cell growth was monitored and the medium changed 
every 2–3 days to achieve an efficient immortalization. After 14 days 
of culture, cells were maintained in complete RPMI 1640 medium 
without cyclosporin A, at a density of approximately 5 × 105 to 
1 × 106 cells/mL.
2.5 | Indirect immunofluorescence assay
Prior to the indirect immunofluorescence assay, the anti-MAG IgM 
titers were determined by ELISA (see below) in Bühlmann titer 
units (BTU). Anti-MAG neuropathy patients’ sera (n = 5) and control 
neuropathy patient sera (n = 1 chronic ataxic neuropathy ophthal-
moplegia M-protein agglutination disialosyl antibodies syndrome 
(CANOMAD) patient and n = 1 chronic inflammatory demyelinating 
polyneuropathy (CIDP) patient with IgM monoclonal gammopathy 
of unknown significance but no MAG or ganglioside activity) were 
used. Both control sera were previously tested for their positive re-
action on sciatic nerves and negative for anti-MAG and anti-ganglio-
side antibodies. The CANOMAD patient sera was tested positive for 
anti-diasialosyl antibodies, however, the exact target of the antibod-
ies in case of the CIDP patient is unknown.
Undiluted sera were incubated for 30 min with different con-
centrations of PPSGG (62.5, 125 and 250 μg/ml in PBS. The sam-
ples were then diluted 1:20 in PBS and incubated for 30 min with 
samples of sciatic nerve cynomolgus monkeys (Macaca fascicularis). 
The non-human primate sciatic nerve samples were part of the 
ImmuGlo™ anti-MAG IFA kit (REF 1172, LOT 1905438B) and ob-
tained from IMMCO Diagnostics. Data were analyzed and quantified 
by ImageJ software from ten fields of observation for each experi-
mental condition.
2.6 | Anti-MAG autoantibodies ELISA
Sera from control subjects, commercially available (n = 1, H4522; 
Sigma-Aldrich) and non-commercial human serum (n = 6), and anti-
MAG neuropathy patients (n = 8) were used to determine the reac-
tivity of PPSGG to other immunoglobulins by ELISA. Maxisorp MP 96 
wells plates (442404; Nunc, Sigma-Aldrich) were coated overnight at 
4°C with 50 µl PPSGG (0.1 µg/ml in PBS), then washed four times with 
300 µl ELISA buffer (0.1% Tween 20 in PBS) and blocked with 100 µl of 
5% bovine serum albumin (BSA, A9647; Sigma-Aldrich) in ELISA buffer 
for 2 hr at 20-25°C. The sera samples were diluted 1:1,000 (2.5% BSA 
in ELISA buffer) and added to the plates after another washing step. 
After incubating for 2 hr at 20-25°C, the plates were washed four times 
with 300 μl ELISA buffer and 100 µl of HRP-labeled anti-human IgM 
(1:2’000 in 1% BSA in ELISA buffer, RRID:AB_258318; Sigma-Aldrich), 
100 µl HRP (horseradish peroxidase)-labeled anti-human IgG (1:10’000 
in 1% BSA in ELISA buffer, RRID:AB_258388; Sigma-Aldrich), or the 
anti-human IgM antibody conjugated to HRP (B-MAG-ELM; Bühlmann 
Laboratories) were added and incubated for 2 hr at 20-25°C, respec-
tively. To develop the assay, 50 µl of undiluted 3,3’,5,5’-tetramethylb-
enzidine (B-TMB; Bühlmann Laboratories) was added and incubated at 
20-25°C on a plate rotator (600 RPM) for 30 min. The stop solution 
490  |     ALIU et AL.
(50 µl of 0.25 M H2SO4) was added and the optical density at 450 nm 
(OD450) was determined within <5 min with the Spectra Max 190 
(Molecular Devices).
2.7 | PPSGG dose titration study in mice
To estimate the dose of PPSGG required to bind and exhaustively elim-
inate anti-MAG IgM autoantibodies in anti-MAG neuropathy patients, 
a dose titration study was performed in mice. Therefore, naïve BALB/c 
mice were intravenously injected with 60 µg (n = 10 mice) or 120 µg 
(n = 8 mice) of purified, sodium azide- and BSA-free anti-HNK-1 IgM 
(ab187274, Abcam), followed by 1–20 µg intravenous doses of PPSGG, 
10–20 min after IgM administration. Blood samples were taken 
5–10 min after PPSGG administration and the serum was collected and 
analyzed for unbound anti-HNK-1 IgM. Additional serum samples were 
taken and analyzed at a later time point (24 hr after administration) 
to confirm the removal of the injected anti-HNK-1 IgM antibodies by 
PPSGG. The detection of the free anti-HNK-1 IgM in mouse sera was 
performed as described elsewhere (Herrendorff et al., 2017).
2.8 | CD20+ cell depletion in mice
BALB/c mice were immunized with purified bovine sulfoglucuronyl 
paragloboside/sulfoglucuronyl-lactosaminyl-paragloboside mixed with 
keyhole limpet hemocyanin (KLH, H8283; Sigma-Aldrich) and TiterMax 
Gold (T2684; Sigma-Aldrich) (Herrendorff et al., 2017). After mouse 
anti-MAG IgM titers plateaued, single intravenous injections (n = 6 mice) 
of 240 µg of anti-mouse CD20 IgG (RRID:AB_2629619; Biolegend) 
or 240 µg of Ultra-LEAF Purified Rat IgG2b (RRID:AB_11149687; 
Biolegend) were performed (n = 3 mice). Blood samples were taken 
prior and at various time points after the treatment and collected in 
ethylenediaminetetraacetic acid (EDTA)-coated tubes from the vena 
saphena. To lyse the erythrocytes, 1 ml of ammonium-chloride-potas-
sium lysing buffer (A10492-01; Gibco, Thermo Fisher Scientific) was 
added at 20-25°C, and after 5 min cells were washed with PBS and 
centrifuged (170 g, 5 min) before repeating the lysis step once more. 
Whole blood (40 µl) was stained with 1 µl of anti-mouse CD19-PECy7 
(RRID:AB_657664; eBioscience) for 45 min at 4°C (protected from 
light). The samples were then diluted with PBS to a final volume of 
200 µl and stained with 1 µl of DAPI (4’,6-diamidino-2-phenylindol, 
D3571; Invitrogen) prior to the analysis of the cells by flow cytometry 
with the LSR Fortessa (Becton Dickinson). At least 10’000 events were 
recorded and data were further gated and analyzed with FlowJo v 10.2 
(FlowJo LLC).
2.9 | Binding of PPSGG to murine and human B cells
The binding of PPSGG to B cells and their potential activa-
tion was studied by flow cytometry and fluorescence micros-
copy. Fluorescently labeled PPSGG (PPSGG, 5% loading with 
sulforhodamine 101) was used to assess binding to the cells and 
Fluo-4 AM was used to determine the intracellular calcium (Ca2+) 
levels as a marker for B cell activation through the B cell receptor 
(Baba & Kurosaki, 2016). Isolated human PBMC, human B cells, mu-
rine splenocytes, and murine B cells were stained with anti-CD19 
PE-Cy7 (mouse anti-human IgG1, RRID:AB_2535491; rat anti-mouse 
IgG2a, RRID:AB_657664) and anti-F4/80 eFluor 450 (rat anti-mouse 
IgG2a, RRID:AB_1548747), Fluo-4 AM (F14201; Thermo Fisher 
Scientific), propidium iodide (PI, P4170; Sigma Aldrich), and Hoechst 
33258 solution (94403; Sigma Aldrich). The cells were loaded with 
3 μM Fluo-4 AM (cell-permeable, fluorescent Ca2+ indicator) for 
30 min in the dark at 37°C and 5% CO2 before the antibodies and 
PPSGG-S were added and incubated for another 30 min. The cells 
were washed once with extracellular solution (135 mM NaCl, 5 mM 
KCl, 5 mM HEPES, 10 mM D-glucose, 2 mM CaCl2, pH 7.35) and kept 
in the dark for the immediate recording.
Isolated murine spleen cells and B cells (n = 6 naïve mice and n = 6 
immunized mice) or PBMC and human B cells (n = 4 anti-MAG neu-
ropathy patients and n = 3 healthy control donors) were incubated at 
approximately 1 × 106 cells/mL with 10 μM or 1 μM PPSGG-S. The 
fluorescently labeled antibodies were added at a concentration of 
1 μL/mL. For assessing B-cell activation, a control measurement was 
recorded to set the gate for the baseline signal and after addition 
of 100 μM unlabeled PPSGG the sample was measured every 2 min 
on a LSR Fortessa (BD Biosciences).Murine cells treated with 3 μM 
Ionomycin acting as a Ca2+ ionophore and EBV transformed human 
B cells showing increased intracellular Ca2+ levels were used as pos-
itive controls. At least 10’000 events were recorded and data were 
analyzed with FlowJo.
The same setup was used to measure binding and activation with 
a fluorescence microscopy (Applied Precision Widefield DV Core 
microscope; GE Life Sciences). B cells were plated in Ibidi 8 well 
µ-Slides (80826; Ibidi GmbH) and loaded with 3 µM Fluo-4 AM and 
incubated with PPSGG-S at 10 µM or 1 µM. The cells were washed 
once with extracellular solution and the plate was placed in a humidi-
fied atmosphere (37°C and 5% CO2) on the microscope using 475 nm 
and 575 nm solid-state illumination and a 60×/1.42 oil-immersion 
objective (Plan Apo N). Five randomly taken spots per sample were 
identified and recorded. According to the flow cytometry experi-
ments, Fluo-4 AM loaded samples were recorded before and after 
addition of 100 µM PPSGG every 5 min for 20 min. The images were 
processed with softWoRx (GE Life Sciences) and analyzed with FIJI 
software. The PPSGG-S binding and the relative changes in intra-
cellular Ca2+ concentration was assessed by measuring fluorescence 
intensity of each individual cell after background subtraction.
2.10 | Dendritic cell activation and intracellular 
cytokine analysis by flow cytometry
Non-adherent monocyte-derived DC (n = 5 healthy control do-
nors) were reseeded at day 6 to a 96-well plate (1 × 105 cells per 
well) in complete RPMI 1640 media and incubated for 1 hr or 18 hr 
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with lipopolysaccharide (LPS) (100 ng/ml), PPSGG (30 μg/ml), or 
both LPS and PPSGG. Afterward, the DC were stained for 20 min 
at 20-25°C with CD14 FITC (RRID:AB_2571928), HLA-DR PerCP 
(RRID:AB_893574), CD40 BV605 (RRID:AB_2564243), CD83 APC 
(RRID:AB_314519), CD11b Alexa Fluor 700 (RRID:AB_493705), 
CD1c APC-Cy7 (RRID:AB_10643413), together with Fc receptor 
block (anti-CD16/32 Ab, RRID:AB_312801) in PBS supplemented 
with 1% BSA. The mean fluorescence intensity (MFI) 16’481 ± 398 
cells per sample was assessed by flow cytometry (LSR Fortessa; BD 
Biosciences).
2.11 | Human interleukin-1β ELISA
Supernatant from PBMC (n = 5 healthy control donors) stimulated 
for 6 hr with lipopolysaccharide (LPS, 100 ng/ml) or PPSGG (30 μg/
ml) in complete RPMI 1640 media (10% FBS, 1% AA, and 1% L-glut) 
was collected and stored at −20°C until use. Total production of 
IL-1β was assessed using the eBioscience™ Human IL-1 beta ELISA 
Ready-SET-Go!™ (Invitrogen™ 88726122) according to the protocol 
provided by the manufacturer (Thermo Fisher).
2.12 | Intracellular cytokine analysis by 
flow cytometry
For the intracellular cytokine analysis, freshly isolated PBMC 
(n = 5 healthy control donors) were reseeded in complete RPMI 
1640 media and stimulated for 2 hr with LPS (100 ng/ml) or PPSGG 
(30 μg/ml) at 37°C and subsequently incubated with a mix of bre-
feldin A and monensin (both diluted 2’000×) for an additional 
4 hr or 18 hr at 37°C. Cells were stained with HLA-DR PerCP 
(RRID:AB_893574), CD8 BV510 (RRID:AB_2561378), CD14 Alexa 
Fluor 700 (RRID:AB_2566715), CD4-PE (RRID:AB_1937246), 
CD11c PE-Alexa Fluor 594 (RRID:AB_2564082), and CD19 PE-
Cy7 (RRID:AB_2564202) together with Fc receptor block (anti-
CD16/32 Ab, RRID:AB_312801). PBMC were then fixed with 4% 
paraformaldehyde in PBS and permeabilized with PBS solution 
containing 0.5% BSA, 0.5% Tween 20, followed by intracellular 
staining with IL-6 FITC (RRID:AB_315151), IL-12/IL-23 p40 Pacific 
Blue (RRID:AB_2124517), TNFα BV605 (RRID:AB_11203719), 
and IL-10 APC (RRID:AB_315456). Data were collected on a 
Fortessa flow cytometer (BD Biosciences) and analyzed using 
FlowJo.
2.13 | Statistical analysis
Unless stated, results are given as mean ± SD of three experiments 
and analyzed by Prism GraphPad Software (Version 7.04). No test for 
outliers was conducted and no data point was excluded in the study. 
The normal distribution was assessed by D'Agostino and Pearson 
normality test. G*Power software (Version 3.1.9.4) was used to de-
termine sample size within the animal approval (No. 2778). No addi-
tional sample calculation was performed for the experiments in this 
publication. Comparisons between two conditions were performed 
using either Student's t test or one-way ANOVA with Dunnett's mul-
tiple comparison posttest with a 0.05 confidence level accepted for 
statistical significance (*p ≤ .05, **p ≤ .01, ***p ≤ .001).
3  | RESULTS
3.1 | Inhibition of patients’ anti-MAG IgM binding 
to myelin of non-human primates and highly selective 
binding of anti-MAG IgM by PPSGG
To assess the potential of PPSGG to inhibit patients’ anti-MAG IgM 
binding to myelin of peripheral nerves, sciatic nerve preparation of 
cynomolgus monkeys were incubated with patients’ sera and the 
myelin reactivity was determined by indirect immunofluorescence 
measurements (Figure 2). The five analyzed sera of anti-MAG neu-
ropathy patients exhibited a wide range of anti-MAG IgM titers 
(6’975, 19’333, 36’383, 61’684, 249’600 BTU). As controls, the sera 
samples of a chronic ataxic neuropathy (CANOMAD) patient and a 
CIDP patient, with IgM monoclonal gammopathy and positive reac-
tion on sciatic nerve but no MAG or ganglioside activity were used. 
They exhibited anti-MAG IgM titers below the threshold of 1’000 
BTU in the ELISA. The normalized fluorescence intensity of all the 
anti-MAG neuropathy patients’ samples decreased by 80% (±5% SD), 
when the sera were incubated with 250 μg/ml PPSGG. The incu-
bation of the anti-MAG neuropathy patients’ samples with 62.5 μg/
ml PPSGG already showed a decrease of 78% (±7% SD) in the nor-
malized fluorescence intensity. The serum of patient 4 exhibiting 
low anti-MAG titer (19’333 BTU) showed residual myelin binding 
compared to patient 2 (61’638 BTU) or 3 (36’383 BTU) with higher 
anti-MAG IgM titers at a PPSGG concentration of 62.5 μg/ml. The 
anti-MAG neuropathy patient 1 with the highest titer showed almost 
a complete decrease in the normalized fluorescence intensity when 
the serum was incubated with 125 μg/ml PPSGG. The control neu-
ropathy patients showed no significant reduction of the normalized 
F I G U R E  2   Selective blocking of the binding of anti-myelin-associated glycoprotein (MAG) IgM from patients sera to sciatic nerve myelin 
of non-human primates. (a) After incubation of undiluted serum (with or without poly(phenyl disodium 3-O-sulfo-β-d-glucopyranuronate)-
(1→3)-β-d-galactopyranoside, PPSGG), the samples were diluted 1 in 20 in phosphate-buffered saline and the myelin-reactivity tested by 
indirect immunofluorescence. (b) Five anti-MAG neuropathy patients’ and two control neuropathy patients’ (chronic ataxic neuropathy 
ophthalmoplegia M-protein agglutination disialosyl antibodies syndrome and chronic inflammatory demyelinating polyneuropathy with IgM 
monoclonal gammopathy of unknown significance but no MAG or ganglioside activity) sera were tested in the indirect immunofluorescence 
assay. A concentration of 125 µg/ml PPSGG completely blocked the binding of anti-MAG IgM to primate sciatic nerve myelin. However, 
(c) PPSGG had no inhibitory activity on the myelin reactivity of the control neuropathy patients
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fluorescence intensity when the undiluted sera were incubated with 
250 μg/ml PPSGG.
To confirm the selective blocking of anti-MAG IgM autoantibod-
ies by PPSGG, the binding of control subject sera (commercial and 
non-commercial), and anti-MAG neuropathy patients’ sera to PPSGG 
was tested. PPSGG showed only reactivity to IgM present in the 
serum samples of anti-MAG neuropathy patients. No reactivity of 
PPSGG to IgM of healthy control samples was detected. Moreover 
in neither control subject sera nor anti-MAG neuropathy patients’ 
sera significant binding of IgG was detected (Figure 3). No signifi-
cant difference in PPSGG reactivity between the commercial and 
non-commercial human serum was observed.
3.2 | Fast and efficient removal of circulating anti-
HNK-1 IgM by PPSGG in BALB/c mice, while CD20+ 
cell depletion showed no significant effect on the 
anti-MAG IgM titers in the immunological mouse 
model for anti-MAG neuropathy
To estimate the PPSGG dose required to reduce anti-MAG IgM au-
toantibody titers in anti-MAG neuropathy patients, we performed 
a dose-finding study in mice (Figure 4). Therefore, naïve BALB/c 
mice were injected with different concentrations of murine anti-
HNK-1 IgM (60, 120 µg/kg) followed by intravenous PPSGG injec-
tion (1–20 µg). Anti-MAG IgM titer analysis in mouse plasma samples 
taken 5–10 min after PPSGG administration showed that the ad-
ministration of a 10 µg PPSGG dose was sufficient to bind 93.28% 
(±0.1% SD) of the 60 µg anti-HNK1 IgM in vivo, as indicated by the 
measured baseline anti-MAG IgM titers. A dose range of 3–5 µg 
was still sufficient to reduce the anti-HNK1 IgM level by ≥ 88.56% 
(±1.64% SD). The lowest dose of 1 µg PPSGG still reduced the 60 µg 
anti-HNK1 IgM level by 23.08% (±0.64% SD) compared to the pre-
treatment level. At the dose of 120 µg anti-MAG IgM, 10 µg PPSGG 
reduced the anti-MAG IgM titers by 97.85% (±0.50% SD), 4 µg 
PPSGG reduced the titers by 88.74% (±8.68% SD), and 2 µg PPSGG 
reduced the titers by 42.71% (±3.03% SD) compared to the pre-
treatment titers. To check whether anti-MAG IgM antibodies were 
permanently removed, mice were sampled at a later time points (24 
and 96 hr after PPSGG administration) and showed persistent reduc-
tion of the titers.
To further verify the mechanism of anti-MAG IgM removal in vivo, 
we compared PPSGG treatment to treatment with a CD20+ B cell de-
pleting monoclonal antibody (Figure 5). Therefore, wild type BALB/c 
mice were immunized against the HNK-1 bearing glycolipids sulfo-
glucuronyl paragloboside/sulfoglucuronyl-lactosaminyl-paraglobo-
side. Once the mice exhibited a constant production of anti-MAG 
IgM antibodies, they were treated either with a single intravenous 
injection of mouse anti-CD20 IgG, rat IgG2b κ isotype control anti-
body, or with weekly injections of PPSGG (10 mg/kg). The number of 
B cells and anti-MAG IgM titers were followed up by flow cytometry 
and ELISA in the blood and serum, respectively. Flow cytometry of 
PBMC revealed the significant depletion of circulating B cells in the 
anti–CD20 antibody treated group, while no significant changes in 
the number of circulating B cell were observed in the IgG2 κ isotype 
control antibody group or PPSGG treated group. However, neither 
B-cell depletion nor IgG2 κ isotype control antibody changed the 
anti-MAG IgM antibody titers significantly during the follow-up pe-
riod of 5 weeks. Only the mice treated once per week with 10 mg/kg 
PPSGG exhibited a significant reduction of the anti-MAG IgM titers.
3.3 | No murine or human leukocyte activation after 
incubation with PPSGG
As PPSGG presents multiple copies of the HNK-1 mimetic, it can be 
seen as multivalent soluble antigen which could be recognized by 
B cells and potentially trigger a humoral response (Heesters et al., 
F I G U R E  3   Reactivity of immunoglobulins (IgG and IgM) from healthy subjects and anti-myelin-associated glycoprotein (MAG) neuropathy 
patients to poly(phenyl disodium 3-O-sulfo-β-d-glucopyranuronate)-(1→3)-β-d-galactopyranoside (PPSGG). A PPSGG-binding ELISA was 
performed with healthy controls (healthy control serum samples n = 7), commercially available normal human serum (n = 1), and anti-MAG 
neuropathy patient samples (n = 8). Only IgM (a) and no IgG (b) binding in sera samples of anti-MAG neuropathy patient exhibited PPSGG 
activity in the ELISA. Data are indicated by mean and standard deviation (one-way ANOVA, *p ≤ .05, **p ≤ .01, ***p ≤ .001)
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2016). Therefore, we assessed if there is specific binding of PPSGG 
to B cells of immunized and non-immunized mice, or to B cells of 
anti-MAG neuropathy patients and of healthy controls (Figure 6). 
Independent of the technique, neither the flow cytometry data nor 
the fluorescent microscopy data showed a significant difference be-
tween control (non-immunized) and anti-MAG IgM and IgG produc-
ing (immunized) B cells isolated from the murine spleen. Nonetheless, 
the percentage of B cells with surface PPSGG staining was highly 
dependent on the concentration of PPSGG. It was increased when 
murine B cells were incubated with 10 μM PPSGG compared to 1 μM 
PPSGG. A sulforhodamine 101 labeled thioglycerol capped poly-l-
lysine backbone was used as control and showed no binding to iso-
lated B cells at 1 or 10 μM. The effect of PPSGG on intracellular Ca2+ 
signaling as a marker for B cell activation was assessed by flow cy-
tometry and fluorescence microscopy (Donjerković & Scott, 2000). 
B cells of immunized and non-immunized mice did not exhibit an 
increase in the relative intracellular Ca2+ levels monitored over the 
time course of 8 min by flow cytometry and 20 min by fluorescence 
microscopy, even after incubation with 100 μM PPSGG. B cells of 
anti-MAG neuropathy patients did not show enhanced binding of 
PPSGG compared to B cells of control subjects, when they were in-
cubated for 30 min with 1 or 10 μM PPSGG.
To confirm the presence of anti-MAG IgM producing B cells in 
the obtained peripheral blood samples from anti-MAG neuropathy 
patients, PBMC of four patients (Nr. 23, 27, 49, and 67) were trans-
formed with EBV to increase viability of B cells ex vivo. Before the 
transformation, the anti-MAG IgM levels of patients 23, 27, and 49 
were higher compared to patient 67. Fourteen days after transfor-
mation, the cell supernatants were analyzed by ELISA for their an-
ti-MAG IgM titers. The cells of patient 49 had the highest anti-MAG 
IgM titer and maintained the ability to secrete anti-MAG IgM in vitro 
(Figure 7). Besides B cells activation, we assessed whether PPSGG 
can induce DC activation by measuring the expression of co-stim-
ulatory molecules (Figure 8). Human monocyte-derived DC (CD1c+, 
CD14-, and CD11b+) were incubated for 18 hr with 30 μg/ml PPSGG, 
100 ng/ml LPS, or with both PPSGG (30 μg/ml) and LPS (100 ng/
ml) and HLA-DR, CD40, and CD83 expression was determined for 
each condition. LPS was used as a positive control for DC activa-
tion and the co-incubation of PPSGG as well as to assess potential 
synergistic effects. We observed that MFI for CD40 and CD83 in-
creased upon LPS exposure, but were unaffected by PPSGG treat-
ment. A trend toward an increased MFI for HLA-DR was observed 
in the LPS-treated groups, but PPSGG had no significant influence 
on the expression of HLA-DR. To assess whether potential pro- or 
anti-inflammatory reactions were induced by PPSGG, freshly iso-
lated PBMC from healthy human donors were treated with 30 μg/
ml PPSGG, 100 ng/ml LPS, or a combination of both for 6 or 20 hr, 
respectively (Figure 9). Subsequently, TNF-α, IL-6, IL-10 and IL-12 
production by CD14+ monocytes and HLA-DR+ CD11c+ DC was as-
sessed by flow cytometry or ELISA. No significant induction of TNF-
α, IL-6, IL-12, and IL-1β was observed, when the CD14+ monocytes 
or CD11c+ DC were incubated with PPSGG. A significant increase 
in the production of TNF-α, IL-6, IL-12, and IL-1β was only observed 
upon treatment with LPS, whereas no impact was observed when 
co-incubating PPSGG with LPS. In addition, to assess potential in-
flammatory or allergic-like reactions induced by the administration 
of PPSGG in BALB/c mice, a cytokine and chemokine array including 
IFNγ, IL-2, IL-6, and TNFα was performed. Neither a single nor mul-
tiple administrations (daily for five consecutive days) of 10 mg/kg 
PPSGG, led to a significant alteration of the studied cytokines and 
chemokines compared to the pre-treatment titers (Figures S1–S5 in 
supplementary information).
4  | DISCUSSION
Anti-MAG neuropathy is a disabling demyelinating peripheral neu-
ropathy with an autoimmune etiology caused by monoclonal IgM 
F I G U R E  4   Poly(phenyl disodium 3-O-sulfo-β-d-glucopyranuronate)-(1→3)-β-d-galactopyranoside (PPSGG) dose titration study in mice. 
The intravenous injection of 60 µg (n = 10 mice) (a) or 120 µg anti-human natural killer-1 (HNK-1) IgM (n = 8 mice) (b) was followed by the 
injection of different doses of PPSGG (<10 min). Blood samples were taken 5 to 15 min after PPSGG administration and the amount of 
PPSGG required to bind most of the administered mouse anti-HNK-1 IgM in circulation was determined by ELISA. The intravenous injection 
of 10 µg was sufficient to deplete ≥ 92% of the total IgM. Data are indicated by mean and standard deviation (one-way ANOVA with 
Dunnett's multiple comparisons test, *p ≤ .05, **p ≤ .01, ***p ≤ .001)
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F I G U R E  5   Effects of anti-CD20 antibody treatment, control antibody treatment, and poly(phenyl disodium 3-O-sulfo-β-d-
glucopyranuronate)-(1→3)-β-d-galactopyranoside (PPSGG) treatment on anti-myelin-associated glycoprotein (MAG) IgM antibodies in the 
immunological BALB/c mouse model for anti-MAG neuropathy. (a) Single injection of 240 µg of anti-CD20 antibody (n = 6) depleted almost 
all circulating CD19+ B cells, whereas weekly PPSGG treatment (10 mg/kg, n = 8) or single treatment with a control rat IgG2b antibody (n = 3) 
did not affect the levels of circulating CD19+ B cells. Weekly PPSGG treatment (10 mg/kg, D1, D8, D15, D22, D28) lowered the anti-MAG 
IgM antibody titers significantly, compared to pre-treatment levels at D0 and depicted by the decreased binding of the anti-human natural 
killer-1 IgM to MAG (n = 5) (b). A single injection of 240 µg of anti-CD20 antibody (c) and of 240 µg (n = 6) of a control antibody (Figures 
S1–S5 in supplementary information) did not affect the anti-MAG IgM antibody titers in mice. Data are indicated by mean and standard 
deviation (one-way ANOVA, *p ≤ .05, **p ≤ .01, ***p ≤ .001).
F I G U R E  6   Concentration-dependent binding of poly(phenyl disodium 3-O-sulfo-β-d-glucopyranuronate)-(1→3)-β-d-galactopyranoside 
(PPSGG) to murine and human B cells without increasing intracellular Ca2+levels. Binding of fluorescently labeled PPSGG to B cells of 
immunized mice (n = 6), control mice (n = 6), anti-myelin-associated glycoprotein (MAG) neuropathy patients (n = 4), and healthy human 
controls (n = 3) were assessed by flow cytometry and fluorescent microscopy. B cells were either incubated with 10 μM and 1 μM PPSGG-S 
or as control with 10 μM and 1 μM fully thioglycerol capped poly-L-lysine backbone labeled with sulforhodamie 101 (a, b). B cells were 
binding PPSGG in a dose-dependent manner and showed no binding to thioglycerol capped poly-L-lysine backbone. There was no difference 
in binding of PPSGG in immunized versus control mice. To confirm that mice were immunized successfully, anti-MAG IgM and IgG titers were 
analysed in sera samples by ELISA (c). Anti-MAG neuropathy patient B cells and B cells from healthy controls were incubated with PPSGG for 
30 min. Anti-MAG neuropathy patient B cells showed lower binding of PPSGG compared to the healthy controls (d). To determine changes 
in intracellular Ca2+ concentration induced by PPSGG binding, murine and human B cells were treated with 100 μM PPSGG after loading 
with 3 μM Fluo-4 AM. The changes in intracellular Ca2+ levels were monitored for the duration of 8 min, in 2 min intervals after a baseline 
measurement and the subsequent addition of 100 μM PPSGG. Neither B cells from immunized mice (e) nor from anti-MAG neuropathy 
patients (f) exhibited increased intracellular Ca2+ concentration after PPSGG incubation. Data are shown as mean values ± SD (unpaired, 
two-tailed t test, *p ≤ .05, **p ≤ .01, ***p ≤ .001)
(b) (c)(a)
(e) (d)(d)
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autoantibodies recognizing the HNK-1 epitope present on MAG as 
well as on other glycoproteins of the peripheral nervous system. 
Previously we have shown the efficient removal of anti-MAG au-
toantibodies by PPSGG in a mouse model for anti-MAG neuropa-
thy (Herrendorff et al., 2017), reflecting the immunological aspects 
of gammopathy with continuous production of polyclonal IgM and 
IgG anti-MAG antibodies. The study suggested a therapeutic po-
tential for PPSGG as a fast-acting antigen-specific agent which se-
lectively targets and eliminates the disease-causing anti-MAG IgM 
autoantibodies. Such a therapeutic could be highly beneficial com-
pared to unselective immunomodulatory or immunosuppressive 
agents currently used to treat anti-MAG neuropathy (Dalakas, 2018; 
Nobile-Orazio, Bianco, Bianco, & Nozza, 2017). In addition to the 
results of the immunological mouse model, we assessed the thera-
peutic potential of PPSGG in a monkey neurological target model. 
Furthermore, the selectivity of anti-MAG IgM binding and potential 
modulatory effects of PPSGG on the immune system were studied. 
Finally, a dose titration study in mice was conducted in preparation 
for first-in-patient clinical trials.
In ex vivo binding studies of patients’ anti-MAG IgM autoanti-
bodies to myelin in cynomolgus monkey sciatic nerve preparations, 
we could demonstrate that myelin reactivity was completely blocked 
when undiluted sera of anti-MAG neuropathy patients were treated 
with PPSGG at low concentrations (250 μg/ml PPSGG), independent 
of anti-MAG IgM autoantibody titers (>70’000—6’975 BTU). The ap-
plied concentration corresponds to a dose of approximately 10 mg/
kg based on the total serum volume of humans. Although, the serum 
sample of patient 4 had only a low anti-MAG IgM autoantibody titer 
of 19’333 BTU, the sample still exhibited residual myelin binding at 
the lowest PPSGG concentration (62.5 μg/ml PPSGG) in contrast to 
the samples of patient A, B, and C with higher titers (>70’000—36’383 
BTU). Importantly, this dose of 62.5 μg/ml, corresponding to a dose 
of approximately 2 mg/kg humans, reduced myelin binding to almost 
the same degree as the higher dose (corresponding to 10 mg/kg).
F I G U R E  7   Anti-myelin-associated glycoprotein (MAG) IgM titers before and after transformation of B cells with Epstein-Barr virus 
(EBV). Antibody titers in the sera of anti-MAG patients and in the supernatants of EBV transformed B cells were determined by ELISA. 
Patients 23, 27, and 49 show high titers of anti-MAG IgM antibodies. Patient 49 exhibited the highest titers in the supernatant after the EBV 
transformation of the B cells, indicating that isolated B cells maintainted their ability to secret anti-MAG IgM after the transformation with 
EBV. Results are shown as mean ± SD
F I G U R E  8   No indication of dendritic cells (DC) activation upon treatment with poly(phenyl disodium 3-O-sulfo-β-d-glucopyranuronate)-
(1→3)-β-d-galactopyranoside (PPSGG) ex vivo. Human monocyte-derived DC (n = 5 donors) were incubated overnight (18 hr) with 
lipopolysaccharide (LPS) (100 ng/ml), PPSGG (30 µg/ml), or the combination of both for 1 hr or 18 hr. DC (CD1c+, CD14-, CD11b+) were gated 
and the mean fluorescence intensity (MFI) for CD40 (a), CD83 (b), and HLA-DR (c) was assessed by flow cytometry. An increase in MFI was 
observed for CD40 and CD83 in LPS-treated groups, but no increase of activation markers was related to PPSGG treatment. Results are 
shown as mean ± SD (one-way ANOVA with Sidak posttest, *p ≤ .05, **p ≤ .01, ***p ≤ .001)
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These results are in line with the finding that anti-MAG IgM au-
toantibodies of different patients can have different affinities to 
the HNK-1 epitope and potentially explain why high anti-MAG IgM 
titers do not necessarily correlate with disease severity (Delmont 
et al., 2019; Ogino, Tatum, Tatum, & Latov, 1994). Selective inhibition 
of IgM binding to myelin was confirmed by the use of sera from two 
control neuropathy patients in the indirect fluorescent assay. Both, 
the CANOMAD and CIDP patients’ sera exhibited IgM binding to 
myelin but no HNK-1 reactivity (<1’000 BTU). Neither of the control 
neuropathy patients’ sera was inhibited by incubation with PPSGG. 
To further confirm selective binding of anti-MAG IgM, we showed 
that PPSGG does not bind to other immunoglobulins of the IgM or 
IgG subclass present in normal human sera.
To corroborate that the dose range of 2–10 mg/kg would be suf-
ficient to deplete circulating anti-MAG autoantibodies in anti-MAG 
neuropathy patients, a dose-finding study in mice, using passive 
immunization with a mouse anti-HNK-1 IgM was performed. The 
intravenous injection of 5 µg PPSGG turned out to be sufficient 
to bind 89.43% (±1.33 SD) of the 60 µg anti-MAG IgM and 10 µg 
PPSGG was sufficient to bind 93.28% (±0.50 SD) of the 120 µg 
anti-HNK-1 IgM. Based on these findings, a dose of approximately 
80 mg PPSGG would be sufficient to bind and remove 1 g of an-
ti-MAG IgM, whereas 40 mg of PPSGG would be sufficient to bind 
and remove most of 1 g anti-MAG IgM autoantibodies in humans. 
Since the anti-HNK-1/MAG IgM antibody levels were reduced for up 
to 2 weeks post-administration of 60 µg anti-HNK-1 IgM and 10 µg 
F I G U R E  9   No significant cytokine production in peripheral blood mononuclear cells (PBMC) upon to poly(phenyl disodium 3-O-sulfo-β-
d-glucopyranuronate)-(1→3)-β-d-galactopyranoside (PPSGG) treatment ex vivo. Freshly isolated human PBMC (n = 5 donors) were treated 
with lipopolysaccharide (LPS) (100 ng/ml), PPSGG (30 µg/ml), or the combination of both for 6 hr or in case of IL-10 production for 20 hr. 
The production of TNFα (a), IL-6 (b), IL-10 (c), and IL-12 (d) by CD14+ monocytes and HLA-DR+ CD11c+ Dendritic cells (DC) was subsequently 
assessed by flow cytometry. Release of IL-1β in the supernatant of incubated cells was assessed by ELISA (e). No significant increase in the 
production of any measured cytokine was observed related to PPSGG treatment. Results are shown as mean ± SD (one-way ANOVA with 
Sidak posttest, *p ≤ .05, **p ≤ .01, ***p ≤ .001)
(b) (c)(a)
(e)(d)
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PPSGG (Figures S1–S5 in supplementary information) and remained 
undetectable, and given the short half-life of PPSGG, we conclude 
that it is a removal rather than a neutralization of the antibodies. 
The pentameric IgM has a molecular weight of 900–1000 kDa and is 
therefore approximately five times heavier than PPSGG with a cal-
culated average weight of 194 kDa. Based on the results of our in 
vivo experiment, the binding stoichiometry of PPSGG:anti-HNK-1 
IgM is around 1:1 to 1:2. In general, the paraprotein (monoclonal an-
ti-MAG IgM) levels in anti-MAG patients are in the range of 1–10 g/L, 
whereas in healthy subjects the total IgM levels are between 0.5 
and 3 g/L (Cook & Macdonald, 2007; Lunn & Nobile-Orazio, 2016). 
Based on a range of 1–10 g/L of monoclonal anti-MAG IgM (3–30 g 
total paraprotein), 240 mg to 2,400 mg of PPSGG are expected to 
be sufficient to completely remove the circulating anti-MAG IgM 
antibodies and at doses of 120–1200 mg most of the paraprotein 
load should be removed. Finally, based on an estimated population 
average of 4 g/L paraprotein, a dose of 1,000 mg PPSGG is expected 
to lead to a complete response for the majority of anti-MAG neurop-
athy patients.
To further evaluate the therapeutic potential of the glycopo-
lymer PPSGG, its efficacy was compared with the B-cell depleting 
treatment by an anti-CD20 IgG antibody in actively immunized mice. 
Anti-CD20 B-cell depletion did not affect the anti-MAG IgM titers in 
mice, whereas PPSGG effectively reduced the antibody titers. The 
former was surprising given the half-life of a murine IgM (2–4 days), as 
it was expected that the significant reduction of B cells would reduce 
IgM titers during the following 5 weeks (Vieira & Rajewsky, 1988). 
Weekly treatment of immunized mice with PPSGG did not affect the 
number of circulating B cells (CD19+). This is consistent with the ob-
servation that PPSGG did not induce or lead to the release of the 
examined murine and human cytokines and chemokines in vivo and 
ex vivo, and did not activate B cells in immunized mice or anti-MAG 
neuropathy patients ex vivo. Given these findings, we conclude that 
the cells responsible for the production of anti-MAG IgM in the im-
munized mouse model are not circulating B cells but rather mature 
plasma cells or late stage B cells (CD20−) residing in the bone mar-
row or a small population of anti-CD20 treatment resistant B cells in 
the spleen (Ahuja, Anderson, Anderson, Khalil, & Shlomchik, 2008; 
DiLillo et al., 2008; Häusler et al., 2018; Hofmann, Clauder, Clauder, 
& Manz, 2018).
In contrast to the immunological murine model, B cells clones 
that produce anti-MAG IgM were successfully isolated from pe-
ripheral blood samples of anti-MAG neuropathy patients and trans-
formed with EBV. They maintained the ability to secrete anti-MAG 
IgM antibodies ex vivo, showing that at least for some patients, an-
ti-MAG IgM-producing B cells (CD20+) can be found in the periphery. 
Based on the observed limited efficacy of anti-CD20 IgG antibody 
treatment, it is likely that the disease has heterogeneous character-
istics in terms of the anti-MAG IgM producing cells (Hammarlund 
et al., 2017; Leger et al., 2013; Nutt, Hodgkin, Hodgkin, Tarlinton, & 
Corcoran, 2015).
Since the immunized mice produce anti-MAG antibodies of both 
the IgM and IgG subtype, we assumed that the mice would have 
memory B cells (CD20-) residing in peripheral lymphoid organs and 
in the circulation (Herrendorff et al., 2017). Nevertheless, we were 
unable to observe a specific binding of the fluorescently labeled gly-
copolymer to B cells isolated from the spleen of immunized mice, 
where the binding of PPSGG could potentiality trigger an immune 
modulation. In B cells challenged with an antigen specific for the 
recognition by its B-cell receptors, a local clustering of these recep-
tors has been observed and the activation of these B cells can be 
monitored by the changes in intracellular Ca2+ levels (Scharenberg, 
Humphries, Humphries, & Rawlings, 2007; Vig & Kinet, 2009).
Since neither in murine nor in human B cells significant changes 
of the intracellular Ca2+ were observed, the sustained antibody 
reduction seen in our previous studies is unlikely driven by B cells 
directly. Furthermore, as there was no induction of peripheral in-
flammatory cytokines and chemokines neither in vivo after single 
and multiple PPSGG administrations in naive mice, nor ex vivo in 
various subpopulation of isolated human and murine leukocytes, we 
assume that the treatment of anti-MAG neuropathy patients with 
PPSGG should not give rise to side effects by inducing acute inflam-
matory markers. However, some caution should be kept as some of 
these experiments were performed in the absence of its target (an-
ti-MAG autoantibodies) and because of the limitations of the in vivo 
and ex vivo models.
5  | CONCLUSION
In contrast to treatments depleting anti-CD20+ cells like rituximab 
or obinutuzumab, PPSGG binds and removes anti-MAG IgM au-
toantibodies highly selectively within minutes. Our findings support 
a mechanism of action of PPSGG leading to a fast and selective in 
vivo depletion of pathogenic anti-MAG IgM autoantibodies, inde-
pendent of the response of anti-MAG neuropathy patient to CD20+ 
B cells depleting treatments. This supports the use of PPSGG as a 
standalone therapy or in combination with immunosuppressive ther-
apeutic agents, possibly at reduced doses, so that patients would 
benefit from both fast removal and long-term suppression of anti-
MAG IgM autoantibody production.
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